| Risk | Moderately High |
|---|---|
| Min SIP Amount | Not Supported |
| Expense Ratio | 1.30% |
| NAV | ₹8.49 (25 Sep 2020) |
|---|---|
| Fund Started | 27 Mar 2018 |
| Fund Size | ₹236 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Bharti Airtel Ltd. | Communication | Equity | 7.0% |
| PI Industries Ltd. | Chemicals | Equity | 6.4% |
| Mahindra & Mahindra Ltd. | Automobile | Equity | 5.7% |
| ITC Ltd. | FMCG | Equity | 5.7% |
| Coromandel International Ltd. | Chemicals | Equity | 5.7% |
| Colgate-Palmolive (India) Ltd. | FMCG | Equity | 5.2% |
| Escorts Ltd. | Automobile | Equity | 5.2% |
| Bayer CropScience Ltd. | Healthcare | Equity | 4.6% |
| Mahindra & Mahindra Financial Services Ltd. | Financial | Equity | 4.4% |
| Rallis India Ltd. | Chemicals | Equity | 4.3% |
UTI Long Term Advantage Fund Series VII Regular Growth is a Equity Mutual Fund Scheme launched by Axis Mutual Fund. This scheme was made available to investors on 27 Mar 2018. Lalit Nambiar is the Current Fund Manager of UTI Long Term Advantage Fund Series VII Regular Growth fund.The fund currently has an Asset Under Management(AUM) of ₹236 Cr and the Latest NAV as of 25 Sep 2020 is ₹8.49.
The UTI Long Term Advantage Fund Series VII Regular Growth is rated Moderately High risk. Minimum SIP Investment is set to 500.
The investment objective of the scheme is to provide medium to long term capital appreciation along with income tax benefit.
Upto Rs. 1.5 lac will be tax free under 80C. Lockin of 3 years. Returns will be taxed at 10%.